Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 7 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

6Total
Not Applicable (1)
Early P 1 (2)
P 2 (3)

Trial Status

Recruiting5
Active Not Recruiting2

Clinical Trials (7)

Showing 7 of 7 trials
NCT06148636Early Phase 1Active Not Recruiting

A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors

NCT06395402Phase 2Recruiting

177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry

NCT05111509Early Phase 1Active Not Recruiting

A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent

NCT04520932Not ApplicableRecruiting

Pancreatic Radiofrequency Under High Echo-endoscopy in the Management of Pancreatic Neuroendocrine Tumors

NCT04464122Recruiting

Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)

NCT06855095Phase 2Recruiting

Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial

NCT06472388Phase 2Recruiting

Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors

Showing all 7 trials

Research Network

Activity Timeline